Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

Atrasentan, an endothelin receptor antagonist, showed clinically significant albuminuria reduction with minimal signs of fluid retention in phase II trials. We evaluated whether plasma exposure was associated with long‐term outcomes for kidney protection and heart failure in the phase III SONAR tria...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Pharmacol Ther
Autori principali: Koomen, Jeroen V., Stevens, Jasper, Bakris, George, Correa‐Rotter, Ricardo, Hou, Fan Fan, Kitzman, Dalane W., Kohan, Donald E., Makino, Hirofumi, McMurray, John J. V., Parving, Hans‐Henrik, Perkovic, Vlado, Tobe, Sheldon W., de Zeeuw, Dick, Heerspink, Hiddo J. L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2021
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8246733/
https://ncbi.nlm.nih.gov/pubmed/33338269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.2143
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi